Stryker Corporation $SYK Shares Bought by Howland Capital Management LLC

Howland Capital Management LLC increased its position in Stryker Corporation (NYSE:SYK) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 126,732 shares of the medical technology company’s stock after acquiring an additional 2,180 shares during the quarter. Stryker comprises approximately 1.2% of Howland Capital Management LLC’s holdings, making the stock its 20th biggest position. Howland Capital Management LLC’s holdings in Stryker were worth $35,012,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in SYK. Bank of America Corp DE bought a new position in shares of Stryker in the second quarter worth approximately $1,404,284,000. Legal & General Group Plc purchased a new stake in shares of Stryker in the second quarter worth $707,212,000. Jupiter Topco LLC bought a new stake in shares of Stryker during the 2nd quarter valued at $681,581,000. Corient Private Wealth LP bought a new stake in shares of Stryker during the 2nd quarter valued at $323,035,000. Finally, Flossbach Von Storch SE purchased a new position in shares of Stryker during the 2nd quarter valued at $464,506,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronda Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. This represents a 2.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 in the last quarter. 4.60% of the stock is currently owned by insiders.

Stryker Stock Up 3.3%

SYK opened at $307.41 on Friday. The company has a market capitalization of $117.91 billion, a PE ratio of 31.86, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78. The firm has a 50-day simple moving average of $295.86 and a two-hundred day simple moving average of $311.96. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the previous year, the firm posted $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts forecast that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SYK. BTIG Research cut their price target on Stryker from $358.00 to $316.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Wells Fargo & Company dropped their price objective on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Citizens Jmp decreased their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $369.00.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.